search
Back to results

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX2)

Primary Purpose

Bronchiectasis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
AZLI
Placebo
Sponsored by
Gilead Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchiectasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male/Female 18 years or older with non-CF bronchiectasis
  • Chronic sputum production on most days
  • Positive sputum culture for gram-negative organisms
  • Must have met lung function requirements

Exclusion Criteria:

  • History of CF
  • Hospitalized within 14 days prior to joining the study
  • Previous exposure to AZLI
  • Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study
  • Must have met liver and kidney function requirements
  • Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed)
  • Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment
  • Other serious medical conditions.

Sites / Locations

  • Florence Research Associates
  • Clinical Trials Connection
  • Phoenix Medical Group
  • Pulmonary Associates
  • AZ Pulmonary Specialists, LTD
  • Pulmonary Consultants & Primary Care Physicians Medical Group, Inc.
  • UC San Diego Medical Center
  • California Pacific Medical Center
  • Georgetown University Hospital
  • University of Florida
  • University of Miami Miller School of Medicine
  • Central Florida Pulmonary Group
  • Sarasota Memorial Hospital - Clinical Research Center
  • Pasadena Center for Medical Research
  • Tampa General Hospital - New Lung Associates
  • Florida Premier Research Institute
  • Southeastern Lung Care PC
  • University of Chicago Medical Center
  • Loess Hills Clinical Research
  • Kentuckiana Pulmonary Associates
  • Pulmonary & Critical Care Associates of Baltimore
  • Robert Wood Johnson Medical School
  • Pulmonary & Allergy Associates, P.A.
  • Jamaica Hospital Medical Center
  • Columbia University, NY Presbyterian Hospital
  • UNC Chapel Hill
  • The Oregon Clinic P.C./ Pulmonary Division
  • University of Pennsylvania Medical Center
  • University of Texas Health Science Center at Tyler
  • University of Utah
  • Pulmonary Consultants, PLLC
  • University of Wisconsin Hospital and Clinics
  • Medical College of Wisconsin Froedtert Hospital
  • Concord Hospital
  • St Vincent's Hospital
  • St George Hospital
  • Royal Perth Hospital
  • Westmead Hospital
  • Royal Adelaide Hospital
  • Repatriation General Hospital
  • Burnside War Memorial Hospital Pharmacy
  • Sir Charles Gairdner Hospital
  • CUB Hôpital Erasme
  • Universitair Ziekenhuis Antwerpen
  • KUL UZ Gasthuisberg
  • Kelowna Respiratory Research and Allergy Clinic
  • The Lung Centre at Vancouver General Hospital
  • St. Michael's Hospital
  • CHICAS - Centre Hospitalier Intercommunal des Alpes du sud, site de GAP
  • Service Activite Ambulatoire Pole Cardiovasculaire Hopital Nord
  • CHU de Montpellier-Hopital Arnaud de Villeneuve
  • Hôpital Pasteur, CHU de Nice
  • Hopital Haut-Leveque
  • CHU Toulouse - Hôpital Larrey
  • Research Center for Medical Studies (RCMS)
  • Charite Campus Virchow-Klinikum
  • Universitätsklinikum Freiburg
  • University Hospital Giessen
  • Medizinische Hochschule Hannover
  • Universitätsklinikum des Saarlandes
  • Universitätsklinikum Jena Clinic for Internal Medicine II
  • Univ.-Klinikum Leipzig, Innere Med.
  • POIS Leipzig GbR
  • Klinikum Innenstadt der LMU Munchen
  • S.Anna Hospital, University of Ferrara
  • UO Broncopneumologia IRCCS Fondazione Cà Granda Milano
  • University of Modena and Reggio Emilia
  • Azienda Universitaria Federico II
  • Università di Pisa - Ospedale Cisanello
  • Ospendale Civile Maggiore Centro Regionale Fibrosi Cistica
  • Medisch Centrum Alkmaar
  • Erasmus MC
  • Hospital Vall d´Hebrón
  • Hospital Clinic i Provincial
  • Hospital Universitario de Bellvitge
  • Hospital Josep Trueta
  • Hospital Universitario La Paz
  • Hospital La Fe
  • Papworth Hospital NHS Trust
  • Royal Infirmary of Edinburgh
  • Royal Devon and Exeter Hospital, NHS Foundation Trust
  • Sir William Leech Centre for Lung Research, Freeman Hospital
  • GBS RE Sheffield Teaching Hospitals NHS Foundation Trust
  • Torbay District General Hospital
  • Royal Wolverhampton Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

AZLI-AZLI

Placebo-AZLI

Arm Description

Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.

Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.

Outcomes

Primary Outcome Measures

Change in QOL-B Respiratory Symptoms Score at Day 28
The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.

Secondary Outcome Measures

Change in QOL-B Respiratory Symptoms Score at Day 84
The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
Time to Protocol-Defined Exacerbation (PDE)
Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria. Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis

Full Information

First Posted
March 11, 2011
Last Updated
March 7, 2014
Sponsor
Gilead Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01314716
Brief Title
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Acronym
AIR-BX2
Official Title
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gilead Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiectasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
274 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AZLI-AZLI
Arm Type
Experimental
Arm Description
Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
Arm Title
Placebo-AZLI
Arm Type
Placebo Comparator
Arm Description
Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
Intervention Type
Drug
Intervention Name(s)
AZLI
Intervention Description
AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo to match AZLI administered via nebulizer three times daily
Primary Outcome Measure Information:
Title
Change in QOL-B Respiratory Symptoms Score at Day 28
Description
The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
Time Frame
Baseline to Day 28
Secondary Outcome Measure Information:
Title
Change in QOL-B Respiratory Symptoms Score at Day 84
Description
The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
Time Frame
Baseline to Day 84
Title
Time to Protocol-Defined Exacerbation (PDE)
Description
Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria. Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis
Time Frame
Baseline to Day 112

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male/Female 18 years or older with non-CF bronchiectasis Chronic sputum production on most days Positive sputum culture for gram-negative organisms Must have met lung function requirements Exclusion Criteria: History of CF Hospitalized within 14 days prior to joining the study Previous exposure to AZLI Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study Must have met liver and kidney function requirements Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed) Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment Other serious medical conditions.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne O'Donnell, MD
Organizational Affiliation
Georgetown University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Florence Research Associates
City
Florence
State/Province
Alabama
ZIP/Postal Code
35630
Country
United States
Facility Name
Clinical Trials Connection
City
Flagstaff
State/Province
Arizona
ZIP/Postal Code
86001
Country
United States
Facility Name
Phoenix Medical Group
City
Peoria
State/Province
Arizona
ZIP/Postal Code
85381
Country
United States
Facility Name
Pulmonary Associates
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
AZ Pulmonary Specialists, LTD
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Facility Name
Pulmonary Consultants & Primary Care Physicians Medical Group, Inc.
City
Orange
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
UC San Diego Medical Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
California Pacific Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
Georgetown University Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
University of Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32209
Country
United States
Facility Name
University of Miami Miller School of Medicine
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Central Florida Pulmonary Group
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Sarasota Memorial Hospital - Clinical Research Center
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Facility Name
Pasadena Center for Medical Research
City
St. Petersburg
State/Province
Florida
ZIP/Postal Code
33707
Country
United States
Facility Name
Tampa General Hospital - New Lung Associates
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Florida Premier Research Institute
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Facility Name
Southeastern Lung Care PC
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033
Country
United States
Facility Name
University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Loess Hills Clinical Research
City
Council Bluffs
State/Province
Iowa
ZIP/Postal Code
51503
Country
United States
Facility Name
Kentuckiana Pulmonary Associates
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Pulmonary & Critical Care Associates of Baltimore
City
Rosedale
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
Facility Name
Robert Wood Johnson Medical School
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Facility Name
Pulmonary & Allergy Associates, P.A.
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07901
Country
United States
Facility Name
Jamaica Hospital Medical Center
City
Jamaica
State/Province
New York
ZIP/Postal Code
11418
Country
United States
Facility Name
Columbia University, NY Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
UNC Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
The Oregon Clinic P.C./ Pulmonary Division
City
Portland
State/Province
Oregon
ZIP/Postal Code
97220
Country
United States
Facility Name
University of Pennsylvania Medical Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Texas Health Science Center at Tyler
City
Tyler
State/Province
Texas
ZIP/Postal Code
75708
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Facility Name
Pulmonary Consultants, PLLC
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
University of Wisconsin Hospital and Clinics
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
Medical College of Wisconsin Froedtert Hospital
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Concord Hospital
City
Concord
State/Province
New South Wales
ZIP/Postal Code
2139
Country
Australia
Facility Name
St Vincent's Hospital
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
St George Hospital
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Facility Name
Royal Perth Hospital
City
Perth
State/Province
New South Wales
ZIP/Postal Code
6000
Country
Australia
Facility Name
Westmead Hospital
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Repatriation General Hospital
City
Daw Park
State/Province
South Australia
ZIP/Postal Code
5041
Country
Australia
Facility Name
Burnside War Memorial Hospital Pharmacy
City
Toorak Gardens
State/Province
South Australia
ZIP/Postal Code
5065
Country
Australia
Facility Name
Sir Charles Gairdner Hospital
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
CUB Hôpital Erasme
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
KUL UZ Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Kelowna Respiratory Research and Allergy Clinic
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1W 1V3
Country
Canada
Facility Name
The Lung Centre at Vancouver General Hospital
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1M9
Country
Canada
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
CHICAS - Centre Hospitalier Intercommunal des Alpes du sud, site de GAP
City
Gap, PACA
ZIP/Postal Code
05007 Cedex
Country
France
Facility Name
Service Activite Ambulatoire Pole Cardiovasculaire Hopital Nord
City
Marseille
ZIP/Postal Code
13015
Country
France
Facility Name
CHU de Montpellier-Hopital Arnaud de Villeneuve
City
Montpellier Cedex 05
ZIP/Postal Code
34295
Country
France
Facility Name
Hôpital Pasteur, CHU de Nice
City
Nice
ZIP/Postal Code
6002
Country
France
Facility Name
Hopital Haut-Leveque
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
CHU Toulouse - Hôpital Larrey
City
Toulouse
ZIP/Postal Code
31054 cedex 9
Country
France
Facility Name
Research Center for Medical Studies (RCMS)
City
Berlin-Charlottenburg (Westend)
ZIP/Postal Code
14052
Country
Germany
Facility Name
Charite Campus Virchow-Klinikum
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
University Hospital Giessen
City
Giessen
ZIP/Postal Code
35392
Country
Germany
Facility Name
Medizinische Hochschule Hannover
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Universitätsklinikum des Saarlandes
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Facility Name
Universitätsklinikum Jena Clinic for Internal Medicine II
City
Jena
ZIP/Postal Code
07747
Country
Germany
Facility Name
Univ.-Klinikum Leipzig, Innere Med.
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
POIS Leipzig GbR
City
Leipzig
ZIP/Postal Code
04357
Country
Germany
Facility Name
Klinikum Innenstadt der LMU Munchen
City
Munich
ZIP/Postal Code
80336
Country
Germany
Facility Name
S.Anna Hospital, University of Ferrara
City
Ferrara
ZIP/Postal Code
44121
Country
Italy
Facility Name
UO Broncopneumologia IRCCS Fondazione Cà Granda Milano
City
Milan
ZIP/Postal Code
20122
Country
Italy
Facility Name
University of Modena and Reggio Emilia
City
Modena
ZIP/Postal Code
41100
Country
Italy
Facility Name
Azienda Universitaria Federico II
City
Naples
ZIP/Postal Code
80131
Country
Italy
Facility Name
Università di Pisa - Ospedale Cisanello
City
Pisa
ZIP/Postal Code
56124
Country
Italy
Facility Name
Ospendale Civile Maggiore Centro Regionale Fibrosi Cistica
City
Verona
ZIP/Postal Code
37124
Country
Italy
Facility Name
Medisch Centrum Alkmaar
City
Alkmaar
ZIP/Postal Code
1815 JD
Country
Netherlands
Facility Name
Erasmus MC
City
Rotterdam
ZIP/Postal Code
3015GD
Country
Netherlands
Facility Name
Hospital Vall d´Hebrón
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clinic i Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital Universitario de Bellvitge
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Josep Trueta
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital La Fe
City
Valencia
ZIP/Postal Code
46009
Country
Spain
Facility Name
Papworth Hospital NHS Trust
City
Cambridgeshire
ZIP/Postal Code
CB23 3RE
Country
United Kingdom
Facility Name
Royal Infirmary of Edinburgh
City
Edinburgh
ZIP/Postal Code
EH16 4SA
Country
United Kingdom
Facility Name
Royal Devon and Exeter Hospital, NHS Foundation Trust
City
Exeter
ZIP/Postal Code
EX5 5AN
Country
United Kingdom
Facility Name
Sir William Leech Centre for Lung Research, Freeman Hospital
City
Newcastle upon Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
GBS RE Sheffield Teaching Hospitals NHS Foundation Trust
City
Sheffield
ZIP/Postal Code
532 1DA
Country
United Kingdom
Facility Name
Torbay District General Hospital
City
Torquay, Devon
ZIP/Postal Code
TQ2 7AA
Country
United Kingdom
Facility Name
Royal Wolverhampton Hospitals NHS Trust
City
Wolverhampton
ZIP/Postal Code
WV10 0QP
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
25154045
Citation
Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep;2(9):738-49. doi: 10.1016/S2213-2600(14)70165-1. Epub 2014 Aug 18.
Results Reference
derived

Learn more about this trial

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

We'll reach out to this number within 24 hrs